Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 263 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Choosing a Gliptin

Gupta Vishal, Kalra Sanjay

Year : 2011| Volume: 15| Issue : 4 | Page no: 298-308

   This article has been cited by
 
1 Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Cristina Mega,Edite Teixeira-de-Lemos,Rosa Fernandes,Flávio Reis
Journal of Diabetes Research. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
2 Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus
Maurílio de Souza Cazarim,Estael Luzia Coelho da Cruz-Cazarim,André de Oliveira Baldoni,Thais Bueno Enes dos Santos,Paula Gonçalves de Souza,Ingrid de Almeida Silva,Roberta Niriam Reis Rodrigues,Alda Cristina Franco Correa Maia,Leonardo Régis Leira Pereira,Cristina Sanches
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;
[Pubmed]  [Google Scholar] [DOI]
3 Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
Khosro Keshavarz,Farhad Lotfi,Ehsan Sanati,Mahmood Salesi,Amir Hashemi-Meshkini,Mojtaba Jafari,Mohammad M. Mojahedian,Behzad Najafi,Shekoufeh Nikfar
DARU Journal of Pharmaceutical Sciences. 2017; 25(1)
[Pubmed]  [Google Scholar] [DOI]
4 Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
Lina Rozano,Muhammad Redha Abdullah Zawawi,Muhamad Aizuddin Ahmad,Indu Bala Jaganath
Advances in Bioinformatics. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
5 The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
Liberata Sportiello,Concetta Rafaniello,Cristina Scavone,Cristiana Vitale,Francesco Rossi,Annalisa Capuano
International Journal of Cardiology. 2016; 202: 731
[Pubmed]  [Google Scholar] [DOI]
6 Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis
Christian Leporini,Rosanna Piro,Francesco Ursini,Francesca Maida,Caterina Palleria,Franco Arturi,Maria Pavia,Giovambattista De Sarro,Emilio Russo
Expert Opinion on Drug Safety. 2016; 15(sup2): 17
[Pubmed]  [Google Scholar] [DOI]
7 Comparison of charges and resource use associated with saxagliptin and sitagliptin
Varun Vaidya,Keyuri Adhikari,Jack Sheehan,Iftekhar Kalsekar
Health Economics Review. 2015; 6(1)
[Pubmed]  [Google Scholar] [DOI]
8 DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello,Liberata Sportiello,Concetta Rafaniello,Francesco Rossi
Expert Opinion on Drug Safety. 2014; 13(S1): 57
[Pubmed]  [Google Scholar] [DOI]
9 Alogliptin for the treatment of Type 2 diabetes
Yutaka Seino,Daisuke Yabe
Expert Review of Endocrinology & Metabolism. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
10 Development of a gas chromatography–mass spectrometry method for the analysis of sitagliptin in human urine
Ebru Uçaktürk
Journal of Pharmaceutical and Biomedical Analysis. 2013; 74: 71
[Pubmed]  [Google Scholar] [DOI]

 

Read this article